Let’s Talk Medtech

Join us for an insightful episode of Let's Talk Medtech, featuring EY's experts John Babitt and Arda Ural. Our guests delve into EY's latest Pulse of the Medtech Industry Report. They take a deep dive into the state of the medtech industry, examining whether the sector is thriving and assessing the real-world impact of tariffs on medical device companies.Discover which medtech segment is experiencing explosive growth right now and learn why mid-tier companies are gaining unprecedented momentum in the marketplace. From industry health assessments to emerging market trends, this episode delivers essential insights for anyone invested in the future of medical technology.Don't miss this comprehensive discussion that addresses the most pressing questions shaping today's medtech landscape.

Welcome back to Let's Talk Medtech, where we're joined by returning guest Paul Grand, CEO of MedTech Innovator, for an essential conversation on securing capital in the medical technology space.In this value-packed episode, Paul reveals why successful fundraising requires a comprehensive, holistic approach rather than a narrow focus. He maps out proven strategies for medtech startups to attract and secure investment at various stages of development, drawing from his extensive experience in the industry.Paul also shares remarkable insights into how MedTech Innovator has successfully connected over 700 promising companies with investors, helping transform innovative ideas into market-ready healthcare solutions.Whether you're a medtech entrepreneur seeking funding, an investor looking for opportunities, or simply interested in the business of medical innovation, this episode delivers actionable wisdom from one of the industry's most respected voices.Subscribe to Let's Talk Medtech for more expert conversations on navigating the complex world of medical technology development and commercialization.

In this episode of Let's Talk Medtech, AngioDynamics CEO James Clemmer shares insights into what has been a transformative year for the medical device company across multiple therapeutic areas.Clemmer highlighted several significant achievements that have strengthened the company's position in both oncology and vascular care. He also describes how a crucial pivot helped redefine AngioDynamics.

MD+DI Senior Editor Amanda Pedersen breaks down the most significant mid-year trends shaping the medical device industry in this insightful episode of Let's Talk Medtech. Get her expert analysis on market developments, regulatory changes, and emerging technologies that are transforming healthcare innovation.Whether you're a medical device professional, healthcare provider, or industry investor, this episode delivers valuable insights to help you navigate the evolving medtech landscape. Subscribe for regular updates on industry news, expert interviews, and in-depth analysis of the technologies revolutionizing patient care.

In a significant industry move this February, Baxter completed the sale of its kidney care business to The Carlyle Group, creating Vantive—a company now experiencing a unique balance of established expertise and newfound agility.CEO Chris Toth recently shared Vantive's ambitious vision, highlighting the firm's commitment to investing over $1 billion in digitally-enabled kidney care solutions. Toth discussed how this strategic separation has empowered the company to maintain its valuable legacy while gaining the flexibility to execute decisions more rapidly.During the conversation, Toth also offered personal insights into his role as a medtech CEO and shared his deep passion for Vantive's mission to transform kidney care.

In this insightful podcast episode, Dr. Martha Morrell, CMO of NeuroPace, shares her transformative journey from academia to pioneering a revolutionary treatment for epilepsy. The RNS System, inspired by cardiac devices, offers targeted stimulation to the brain, tailoring interventions to each patient's needs. Dr. Morrell discusses the challenges and triumphs of steering such an innovation to FDA approval. Her story highlights the intersection of expertise, perseverance, and multi-disciplinary collaboration in MedTech, setting a new precedent for epilepsy treatment.

Peter Shen leads the Digital & Automation business at Siemens Healthineers North America. With over 25 years of experience in healthcare digitalization, he has held several executive management roles across sales, marketing, and innovation, with a focus on driving the adoption of new and emerging technologies. Notably, Peter has testified before Congress multiple times, advocating for the benefits of AI and championing new federal healthcare reimbursement policies. Find out what he has to say about Siemens Healthineers using AI to help enrich patients’ lives in this all-new episode of Let’s Talk Medtech.

In this episode of Let's Talk MedTech, Omar chats with Jijo James, Chief Medical Officer for Johnson & Johnson MedTech and Interventional Oncology. James shares insights into J&J's commitment to patient safety, discussing how the company combines clinical safety, safety science, and bioethics to ensure safe and effective outcomes for patients. He highlights the importance of the operator in medical device procedures and how J&J is improving safety through innovative tools like the device briefing tool. James also discusses the challenges of device-related interruptions during surgeries, emphasizing the need for better communication and proactive strategies to avoid complications. This is a fascinating conversation for anyone interested in healthcare innovation and patient safety in the medtech industry!

Ha Hong, Chief AI Officer at Medtronic Endoscopy, joins us to talk about how the company is embracing artificial intelligence. He'll also discuss the trends he's seeing with AI in the medical device industry on this brand-new episode of Let's Talk Medtech.

Jennifer Samproni, CTO of Flex, discusses the importance of human-machine interface innovation and strategies for medical device designers and manufacturers.

EY’s John Babbitt and Jim Welch join us for this episode to dive deeply into the Pulse of the Medtech Industry Report. We’re talking about deals, IPOs, the hottest segments, and more in this incredible episode of Let’s Talk Medtech.

Interested in designing medical device products? Want to know the do's and dont's of medtech design? Then you must listen to this all-new episode of Let's Talk Medtech featuring BlackHägen Design's Philip Remedios and Renee Bailey. Both will talk about what you need to have in mind when building device and breakdown how Contextual Inquiry is changing how we think about medtech design.

Upma Sharma joins us for this episode of Let's Talk Medtech to discuss how Arsenal Medical is developing biomaterials that are changing the way medicine is practiced. Sharma also discusses her evolution from a researcher to CEO of a medtech company.

Scott Nelson, one of the medical device's top insiders, stops by to discuss the trends in the industry and to give tips to entrepreneurs looking to jump into the world of medtech. Nelson is the co-founder and CEO of FastWave Medical, a medical device startup developing intravascular lithotripsy systems for cardiovascular disease. Additionally, he’s the founder of Medsider, where he interviews founders and CEOs of promising, early-stage medical device and health technology companies. 

Dana Brown, iCAD's president, chairman and CEO, shares how the company is changing the way we think about breast cancer detection. Brown gives us an update on the partnership with Google. Plus, she talks about her time at Susan G. Komen and how cancer detection has changed throughout the years. She also gives some tips for aspiring medtech professionals in this new episode of Let's Talk Medtech.Omar : How are you?Dana: Great. Thanks for having me.Omar: I'm doing well, just a bit sleep-deprived with a newborn at home, but otherwise, all good.Dana: Congratulations.Dana: Thank you. So, Dana, it's been over a year since you took the reins at iCAD. How has the journey been so far?Dana: Better than I expected, honestly. I joined ICAD's board over two years ago, initially thinking it was my dream role. But I saw an opportunity to contribute more directly given my background in cloud technologies and breast health. Jumping in has been fantastic—the team is great, and seeing our solutions in action, not just on paper, has been incredibly rewarding.Omar: That's wonderful to hear. Before we dive into iCAD, let's talk about your time at Susan G. Komen. Can you share about your role there?Dana: Sure, at Susan G. Komen, I served as the chief strategic and operations officer for nearly five years. My focus was enhancing direct patient engagement, ensuring initiatives like helplines, financial aid, and support resources were impactful and accessible. It was about making sure Komen's efforts directly benefited patients throughout their breast cancer journey.Omar: How have your experiences at Komen influenced your approach at iCAD?Dana: Three main takeaways: continuous learning, particularly in management and collaboration; leveraging technology like EMRs and research registries to enhance patient care; and fostering a culture of innovation, crucial for developing effective solutions in breast health.Omar: It sounds like a wealth of knowledge to bring to iCAD. Speaking of which, let's touch on iCAD's use of AI in breast cancer detection. How is AI reshaping mammography?Dana: AI has revolutionized mammography by enhancing accuracy and efficiency. Unlike human eyes, AI processes data at a granular level, making it a reliable second opinion for radiologists. Beyond cancer detection, we're exploring applications like detecting breast arterial calcification, offering a more holistic view of a patient's health.Omar: That's impressive—AI as a precision tool in healthcare. Is it making mammogram results more understandable for patients?Dana: Currently, AI primarily aids clinicians by providing trusted decision support. However, patients are becoming aware of AI's role and its potential to offer them clearer, faster insights into their health—a promising development we're exploring further.Omar: Moving forward, iCAD has partnered with Google Health. What can you tell us about this collaboration?Dana: Our collaboration with Google Health spans two key initiatives: integrating our technology into Google's cloud infrastructure for seamless healthcare operations, and jointly developing advanced AI algorithms. This includes creating an AI-powered second reader for mammograms, aiming to streamline diagnosis and reduce turnaround times, addressing the shortage of radiologists globally.Omar: That's a significant step forward in leveraging technology for healthcare efficiency. While we await regulatory clearances, how do you see AI influencing patient care in the future?Dana: AI is empowering patients with knowledge and enabling more informed healthcare decisions. It's part of a broader trend towards patient empowerment, where individuals actively engage in their health management—a positive shift we're committed to advancing at ICAD.Omar: Your...

European Union states greenlit a measure to regulate artificial intelligence. The sweeping law is the first of its kind and will have a definitive impact on any companies that employ the use of AI. Anne-Gabrielle Haie, a partner with Steptoe LLP, answers questions about the AI Act and discusses its potential impact on the medical device industry in this all-new episode of Let's Talk Medtech.

MD&M West is a tradeshow that boasts some of the best speakers in the medical device industry - and Let's Talk Medtech has snagged its keynote speaker, Jennifer Samproni for this can't miss episode.Jennifer is the Chief Technology Officer, of Health Solutions at Flex, and drops by to shed some light on her keynote speech - Transforming the Future of Patient Care with Human Machine Interfaces. She'll also talk about how artificial intelligence is changing healthcare; why contract manufacturing is booming; and give tips on navigating the medical device industry in this season opener of Let's Talk Medtech.

MD+DI's Senior Editor, Amanda Pedersen joins us for this episode of Let's Talk Medtech to look at what 2023 was for the medical device and diagnostics industry. The veteran journalist also dives into what the future might hold in 2024 for the industry.

Benjamin Zegarelli, counsel with Mintz, gives some important regulatory updates surrounding laboratory-developed tests, artificial intelligence, and software. Oh yeah, we talk about a little thing called EU MDR in this new episode of Let's Talk Medtech.

Surbhi Sarna began her journey into medtech when she had a health scare at the age of 13. The ordeal led her to founding nVision, a company focused on the detection of ovarian cancer. nVision was eventually acquired by Boston Scientific. Sarna joins us shortly before her keynote at BIOMEDevice Silicon Valley to discuss her journey into medtech and what it takes to be an entrepreneur in the industry.